Integrative Clinical Genomics of Advanced Prostate Cancer

Cell - Tập 161 - Trang 1215-1228 - 2015
Dan Robinson1,2, Eliezer M. Van Allen3,4, Yi-Mi Wu1,2, Nikolaus Schultz5,6, Robert J. Lonigro1, Juan-Miguel Mosquera7,8,9,10, Bruce Montgomery11,12, Mary-Ellen Taplin3, Colin C. Pritchard13, Gerhardt Attard14,15, Himisha Beltran8,9,16,10, Wassim Abida17,18, Robert K. Bradley11, Jake Vinson19, Xuhong Cao1,20, Pankaj Vats1, Lakshmi P. Kunju1,2,21, Maha Hussain22,21,23, Felix Y. Feng1,21,24, Scott A. Tomlins1,2,21,23
1Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
2Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
4Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA
5Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
6Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
7Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
8Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
9New York Presbyterian Hospital, New York, NY 10021, USA
10Meyer Cancer, Weill Medical College of Cornell University, New York, NY 10021, USA
11Computational Biology Program, Public Health Sciences Division and Basic Science Division, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 98109, USA
12Department of Medicine and VAPSHCS, University of Washington, Seattle, WA 98109, USA
13Department of Laboratory Medicine, University of Washington, Seattle, WA 98195 USA
14Cancer Biomarkers Team, Division of Clinical Studies, The Institute of Cancer Research, London SM2 5NG, UK
15Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London SM2 5NG, UK
16Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
17Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
18Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
19Prostate Cancer Clinical Trials Consortium, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
20Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA
21Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA
22Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
23Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
24Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA

Tài liệu tham khảo

American Cancer Society (2015). Cancer Facts and Figures 2015. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf. Antonarakis, 2014, AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer, N. Engl. J. Med., 371, 1028, 10.1056/NEJMoa1315815 Asangani, 2014, Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer, Nature, 510, 278, 10.1038/nature13229 Assié, 2014, Integrated genomic characterization of adrenocortical carcinoma, Nat. Genet., 46, 607, 10.1038/ng.2953 Baca, 2013, Punctuated evolution of prostate cancer genomes, Cell, 153, 666, 10.1016/j.cell.2013.03.021 Barbieri, 2012, Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer, Nat. Genet., 44, 685, 10.1038/ng.2279 Beer, 2014, Enzalutamide in metastatic prostate cancer before chemotherapy, N. Engl. J. Med., 371, 424, 10.1056/NEJMoa1405095 Beltran, 2013, Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity, Eur. Urol., 63, 920, 10.1016/j.eururo.2012.08.053 Berger, 2011, The genomic complexity of primary human prostate cancer, Nature, 470, 214, 10.1038/nature09744 Cao, 2013, PLZF mediates the PTEN/AKT/FOXO3a signaling in suppression of prostate tumorigenesis, PLoS ONE, 8, e77922, 10.1371/journal.pone.0077922 Carreira, 2014, Tumor clone dynamics in lethal prostate cancer, Sci. Transl. Med., 6, 254ra125, 10.1126/scitranslmed.3009448 Castro, 2013, Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer, J. Clin. Oncol., 31, 1748, 10.1200/JCO.2012.43.1882 Cerami, 2012, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov., 2, 401, 10.1158/2159-8290.CD-12-0095 Cibulskis, 2013, Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples, Nat. Biotechnol., 31, 213, 10.1038/nbt.2514 Comstock, 2013, Targeting cell cycle and hormone receptor pathways in cancer, Oncogene, 32, 5481, 10.1038/onc.2013.83 Cooper, 2015, Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue, Nat. Genet., 47, 367, 10.1038/ng.3221 de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N. Engl. J. Med., 364, 1995, 10.1056/NEJMoa1014618 Epstein, 2014, Proposed morphologic classification of prostate cancer with neuroendocrine differentiation, Am. J. Surg. Pathol., 38, 756, 10.1097/PAS.0000000000000208 Finn, 2015, The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study, Lancet Oncol., 16, 25, 10.1016/S1470-2045(14)71159-3 Fong, 2009, Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers, N. Engl. J. Med., 361, 123, 10.1056/NEJMoa0900212 Futreal, 2004, A census of human cancer genes, Nat. Rev. Cancer, 4, 177, 10.1038/nrc1299 Gao, 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci. Signal., 6, pl1, 10.1126/scisignal.2004088 Gao, 2014, Organoid cultures derived from patients with advanced prostate cancer, Cell, 159, 176, 10.1016/j.cell.2014.08.016 Geng, 2013, Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover, Proc. Natl. Acad. Sci. USA, 110, 6997, 10.1073/pnas.1304502110 Giannakis, 2014, RNF43 is frequently mutated in colorectal and endometrial cancers, Nat. Genet., 46, 1264, 10.1038/ng.3127 Grasso, 2012, The mutational landscape of lethal castration-resistant prostate cancer, Nature, 487, 239, 10.1038/nature11125 Gundem, 2015, The evolutionary history of lethal metastatic prostate cancer, Nature, 520, 353, 10.1038/nature14347 Hieronymus, 2014, Copy number alteration burden predicts prostate cancer relapse, Proc. Natl. Acad. Sci. USA, 111, 11139, 10.1073/pnas.1411446111 Hong, 2015, Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer, Nat. Commun., 6, 6605, 10.1038/ncomms7605 Hsieh, 2015, PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy, Cancer Res., 10.1158/0008-5472.CAN-14-3602 Kaufman, 2015, Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation, J. Clin. Oncol., 33, 244, 10.1200/JCO.2014.56.2728 Kikugawa, 2006, PLZF regulates Pbx1 transcription and Pbx1-HoxC8 complex leads to androgen-independent prostate cancer proliferation, Prostate, 66, 1092, 10.1002/pros.20443 Kim, 2011, TopHat-Fusion: an algorithm for discovery of novel fusion transcripts, Genome Biol., 12, R72, 10.1186/gb-2011-12-8-r72 Lalonde, 2014, Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study, Lancet Oncol., 15, 1521, 10.1016/S1470-2045(14)71021-6 Lawrence, 2013, Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature, 499, 214, 10.1038/nature12213 Lawrence, 2014, Discovery and saturation analysis of cancer genes across 21 tumour types, Nature, 505, 495, 10.1038/nature12912 Liu, 2013, Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974, Proc. Natl. Acad. Sci. USA, 110, 20224, 10.1073/pnas.1314239110 Lonigro, 2011, Detection of somatic copy number alterations in cancer using targeted exome capture sequencing, Neoplasia, 13, 1019, 10.1593/neo.111252 Mateo, 2014, Antitumour activity of the PARP inhibitor olaparib in unselected sporadic castration-resistant prostate cancer (CRPC) in the TOPARP trial, Annals Oncol., 25, 1, 10.1093/annonc/mdu438.20 Mehra, 2011, Characterization of bone metastases from rapid autopsies of prostate cancer patients, Clin. Cancer Res., 17, 3924, 10.1158/1078-0432.CCR-10-3120 Olshen, 2004, Circular binary segmentation for the analysis of array-based DNA copy number data, Biostatistics, 5, 557, 10.1093/biostatistics/kxh008 Palanisamy, 2010, Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma, Nat. Med., 16, 793, 10.1038/nm.2166 Pflueger, 2011, Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing, Genome Res., 21, 56, 10.1101/gr.110684.110 Pritchard, 2014, Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer, Nat. Commun., 5, 4988, 10.1038/ncomms5988 Robinson, 2011, Integrative genomics viewer, Nat. Biotechnol., 29, 24, 10.1038/nbt.1754 Roychowdhury, 2011, Personalized oncology through integrative high-throughput sequencing: a pilot study, Sci. Transl. Med., 3, 111ra121, 10.1126/scitranslmed.3003161 Ryan, 2013, Abiraterone in metastatic prostate cancer without previous chemotherapy, N. Engl. J. Med., 368, 138, 10.1056/NEJMoa1209096 Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N. Engl. J. Med., 367, 1187, 10.1056/NEJMoa1207506 Schwartz, 2015, Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ, Cancer Cell, 27, 109, 10.1016/j.ccell.2014.11.008 Seshagiri, 2012, Recurrent R-spondin fusions in colon cancer, Nature, 488, 660, 10.1038/nature11282 Taplin, 1995, Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer, N. Engl. J. Med., 332, 1393, 10.1056/NEJM199505253322101 Taylor, 2010, Integrative genomic profiling of human prostate cancer, Cancer Cell, 18, 11, 10.1016/j.ccr.2010.05.026 The Cancer Genome Atlas. (2015). The molecular taxonomy of primary prostate cancer. http://www.cbioportal.org/study.do?cancer_study_id=prad_tcga_pub. Thorvaldsdóttir, 2013, Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration, Brief. Bioinform., 14, 178, 10.1093/bib/bbs017 Tomlins, 2005, Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer, Science, 310, 644, 10.1126/science.1117679 Tomlins, 2007, Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer, Nature, 448, 595, 10.1038/nature06024 Trapnell, 2012, Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks, Nat. Protoc., 7, 562, 10.1038/nprot.2012.016 Van Allen, 2014, Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy, Prostate Cancer Prostatic Dis., 17, 23, 10.1038/pcan.2013.37 Van Allen, 2014, Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma, Cancer Discov., 4, 1140, 10.1158/2159-8290.CD-14-0623 Van Allen, 2014, Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine, Nat. Med., 20, 682, 10.1038/nm.3559 Voeller, 1998, Beta-catenin mutations in human prostate cancer, Cancer Res., 58, 2520 Wang, 2011, Characterization of KRAS rearrangements in metastatic prostate cancer, Cancer Discov., 1, 35, 10.1158/2159-8274.CD-10-0022 Wee, 2008, PTEN-deficient cancers depend on PIK3CB, Proc. Natl. Acad. Sci. USA, 105, 13057, 10.1073/pnas.0802655105 Weston, 2010, The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo, Blood, 116, 4578, 10.1182/blood-2010-01-265769
Thông tin
Thông tin xuất bản

Cell

Tập 161

1215-1228

Thông tin tác giả